Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma

Table 1

Summary of use of trastuzumab in Her2 overexpressed metastatic SDCs.

Study ID	Method	𝑛	Chemotherapy used concurrently	Response	Outcome
Haddad et al., 2003 [13]	Phase II trial	14	No	1/14 PR	Median time to progression 4.2 months
Limaye et al., 2013 [17]	Retrospective; case series	5*	Carboplatin/paclitaxel	1/5 CR; 2/5 PR	Median duration of response 18 months; (range: 8–52 months)
Kadowaki et al., 2013 [18]	Case report	1	Paclitaxel	CR	13-month f/u. No disease progression
Firwana et al., 2012 [19]	Case report	1	Paclitaxel	CR (of liver metastases)	Alive. Stable after 16 months of f/u
Nashed and Casasola, 2009 [20]	Case report	1	Initially doxorubicin then docetaxel	PR**	Alive. 20 months since metastatic disease
Prat et al., 2008 [21]	Case report	1	Carboplatin/palclitaxel	CR	Alive. No disease progression in 14 months f/u
Sharon et al., 2010 [22]	Case report	1	Capecitabine/zoledronic acid	CR	Alive. No disease progression in 2-year f/u
Kaidar-Person et al., 2012 [23]	Case report	1	Carboplatin/paclitaxel	CR	Alive. Duration unrecorded
Locati et al., 2005 [24]	Cases series	4	Yes (not specified)	1/4 SD	Median time to progression 2.5 months

𝑛: number of patients. PR: partial response. CR: complete response. SD: stable disease. f/u: follow-up.
*Out of total 13 patients, 8 were treated adjuvantly and 5 were metastatic. **CR in lung and liver and minimal residual disease in neck.